

OREXO CONVERTS FUTURE RIGHTS FOR OX-MPI TO SHARES IN GESYNTA PHARMA VALUED AT SEK 19 MILLION

Uppsala, Sweden – January 20, 2025 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma AB (“Gesynta”). The transaction took place in connection with Gesynta's recent capital raise and Orexo's shares are valued at SEK 19.2 million. The value generated will be recognized under other operating income in Orexo's Q4, 2024 results.

In 2017, Orexo and Gesynta entered into a purchase agreement under which Gesynta acquired all assets related to OX-MPI, with the intention of developing the drug candidate. In return, Orexo was entitled to receive share of future transaction proceeds and royalty on future net revenues generated from the program.

With successful fundraising, Gesynta will now proceed with development of vipoglanstat in a phase II clinical trial. The drug candidate has the potential to revolutionize the treatment of the inflammatory disease endometriosis, which affects 190 million women worldwide.

Nikolaj Sørensen, CEO and President of Orexo AB said: *“We are pleased to see the support from investors to Gesynta and the continued development of vipoglanstat. The early data from vipoglanstat is impressive and the drug candidate has the potential to help millions of women worldwide living with the chronic disease endometriosis. Orexo looks forward to continue as a shareholder in Gesynta and this transaction is fully in line with our objective of strengthening the Orexo financial results and equity position.”*

**For further information contact:
Orexo AB (publ.)**

Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

About Gesynta Pharma

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1, a key enzyme in inflammatory processes. Gesynta Pharma's research originated at Karolinska Institutet in Sweden.

The lead compound, vipoglanstat, is being developed for the treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to a severely reduced quality of life and current drug treatments are inadequate for many patients, partly due to troublesome side effects. Vipoglanstat is a non-hormonal, non-opioid, disease-modifying drug candidate that selectively inhibits mPGES-1; it has demonstrated a favorable safety profile and potent inhibition of mPGES-1 in Phase I and II clinical trials. A preclinical proof-of-concept study in an advanced disease model of endometriosis shows that vipoglanstat significantly reduces endometrial lesions and positively impacts pain-related parameters and well-being. A Phase II clinical trial in patients with endometriosis is expected to start in 2025.

A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase I for the treatment of chronic inflammatory pain.

The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, and other internationally renowned specialist investors. For more information, please visit www.gesynta.se.

The information was submitted for publication, through the agency of the contact persons set out above, at 8.45 CEST on January 20, 2025.

Attachments

Orexo converts future rights for OX-MPI to shares in Gesynta Pharma valued at SEK 19 million